The impetus behind these fellowships lies in the rapidly expanding availability of large-scale biological datasets and the increasing necessity for sophisticated computational frameworks to interpret them. Yung S. Lie, PhD, President and CEO of the Damon Runyon Cancer Research Foundation, emphasizes the crucial role of computational expertise in precision medicine, where modeling and data integration are vital for dissecting tumor heterogeneity and treatment responses. The selected fellows epitomize this interdisciplinary approach, bridging “dry” lab quantitative sciences with “wet” lab biological insights to pioneer novel avenues in cancer understanding and intervention.

Among the fellowship recipients is Dr. Minsoo Kim, who focuses on the enigmatic presence of aneuploid cells—cells with abnormal chromosome numbers—in ostensibly healthy breast tissue. Challenging long-held assumptions that normal cells uniformly maintain chromosomal integrity, Dr. Kim’s research investigates these rare aneuploid populations as potential early harbingers of breast cancer. By developing a heterogeneous graph neural network (GNN), his work will jointly model single-cell copy number variations and gene expression data, representing genes, cells, and chromosome segments as distinct nodes. This nuanced modeling approach aims to disentangle gene expression changes driven by chromosomal gains or losses from other transcriptional variations.

Crucially, Dr. Kim intends to extend this computational framework into spatial transcriptomics, which retains the spatial context of gene expression within tissue architecture. This enhancement is designed to illuminate how the microenvironment influences aneuploid cell behavior and interactions, potentially revealing biomarkers for early detection and mechanisms of cancer risk stratification. By applying these analyses to longitudinal breast tissue samples from patients monitored over years, where some subsequently developed cancer, the project aspires to not only refine predictive diagnostics but also offer clinicians tools for earlier, more targeted intervention strategies.

Dr. Sahana Kuthyar’s research addresses a pressing clinical challenge: the elevated risk of severe lung infections in cancer patients undergoing immunosuppressive therapies like chemotherapy and radiation. These treatments, while efficacious against tumors, impair myeloid immune components critical for combating bacterial pathogens, leaving patients vulnerable to conditions such as pneumonia. Moreover, the common clinical practice of providing supplemental oxygen further complicates this risk by altering the pulmonary environment to favor aggressive bacterial proliferation. Dr. Kuthyar’s investigation bridges human and murine models to unravel this complex interplay.

Her computational strategy leverages hierarchical network modeling to integrate gene expression profiles with metabolomic data, applying multi-omics factor analysis for a holistic view of microbial and host immune dynamics under hyperoxic conditions. By cross-validating predictive models between human patients and mouse models, the study aims to iteratively refine understanding of how bacterial adaptation and immune suppression converge to create critical infection vulnerabilities. The insights garnered here may pave the way for predictive diagnostics and novel therapeutic approaches to mitigate life-threatening infections in immunocompromised cancer populations.

Matthew Leventhal, PhD, embarks on a pioneering inquiry into sex chromosome biology within cancer, focusing on the differential roles of active and inactive X chromosomes in females—a subject deeply intertwined with oncogenic potential. Given that females carry two X chromosomes with one subjected to early developmental silencing, mutations impacting the active X chromosome may have outsized consequences on cellular function and tumor progression. Dr. Leventhal’s work centers on developing computational tools capable of resolving the haplotype-specific copy number of chromosomes from bulk whole-genome sequencing data, correcting phasing errors that have historically obscured distinctions between active and inactive X chromosome alterations.

Integrating DNA sequencing with RNA-seq expression data, this methodology will allow for the first pan-cancer analysis of X chromosome dynamics across more than 8,500 tumors spanning 31 cancer types. The goal is to identify recurrent copy number alterations preferentially affecting either the active or inactive X, potentially uncovering novel oncogenic drivers or vulnerabilities previously masked due to analytical limitations. Additionally, determining whether such chromosomal alterations exist in precancerous cells could have transformative implications for early detection and intervention strategies tailored to sex chromosome biology.

The innovations promised by these fellows are testament to the evolving landscape of cancer research, where computational advancements are indispensable to dissecting biological complexity. The utilization of graph neural networks, multi-omics integration, and sophisticated haplotype phasing models exemplifies the next frontier of oncological inquiry, promising heightened precision in diagnosis, prognosis, and treatment. Beyond their individual research agendas, these scientists exemplify the Damon Runyon Foundation’s vision of cultivating interdisciplinary talent equipped to unravel cancer’s multifaceted biology.

Since 1946, the Damon Runyon Cancer Research Foundation has championed early-career investigators, recognizing that the initial years of scientific pursuit are critical for unleashing transformative discoveries. Over $491 million invested and nearly 4,100 funded scientists reflect an enduring commitment to nurturing high-risk, high-reward research. The foundation’s outstanding track record, highlighted by thirteen Nobel laureates among its alumni, underscores its impact on the global cancer research community.

These current fellowships reinforce the need to blur conventional boundaries between computational and biological sciences, reinforcing a paradigm where machine learning algorithms and spatial data are indispensable complements to experimental biology. As the biological sciences grapple with data of unprecedented scale and complexity, the fusion of quantitative expertise and biological insight will catalyze breakthroughs in understanding cancer’s origins, progression, and treatment resistance.

The relevance of this fellow-supported research extends to personalized and precision medicine, where patient-specific molecular data can guide tailored therapeutic regimens. Detecting early aneuploid cell populations, predicting infection risks in susceptible patients, and elucidating sex chromosome influences represent concrete ways in which computational biology is reshaping cancer care. Through these fellowships, the Damon Runyon Foundation equips young scientists with not only resources but also mentorship from leaders in computational and biological cancer research, creating a fertile environment for interdisciplinary innovation.

As these fellows progress, their work is poised to impact fundamental understanding and clinical strategies alike. Whether refining early detection algorithms for breast cancer, unearthing microbial-immune crosstalk in cancer-associated pneumonia, or decoding X chromosome alterations across cancers, these efforts embody a new wave of cancer research empowered by computational sophistication. The field awaits the ripple effects of their discoveries as they translate complex biological data into actionable knowledge with the potential to save lives.

In sum, the 2026 Damon Runyon Quantitative Biology Fellows symbolize a convergence of technology and biology at a pivotal moment in cancer research. Their ambitious projects harness state-of-the-art computational methodologies to tackle profound questions about cancer initiation, progression, and patient vulnerability. Supported by visionary funding and mentorship, these scholars exemplify the future of biomedical research, where multidisciplinary collaboration and quantitative prowess unlock mysteries once deemed impenetrable.

Subject of Research: Computational approaches to cancer biology focusing on early detection, infection risk in immunocompromised patients, and sex chromosome genomics in cancer.

Article Title: Unlocking Cancer’s Complexities: How Computational Pioneers are Shaping the Future of Oncology

News Publication Date: 2026

Web References: http://damonrunyon.org/

Keywords: cancer research, computational biology, machine learning, graph neural networks, spatial transcriptomics, multi-omics analysis, cancer immunology, X chromosome, aneuploidy, precision medicine, early cancer detection, network modeling

The ACC initiative, established in 2011, represents a multi-million-dollar commitment uniting some of the most influential players in cancer research and drug development. Industry partners span a formidable roster, including AbbVie, Amgen, ARIAD, Celgene, Eli Lilly and Company, Genentech, Gilead, Merck, Novartis, Pfizer, and Takeda Pharmaceuticals. This unique partnership underlines the intensified focus on collaborative innovation necessary to combat cancer’s complex molecular and clinical landscape. The synthesis of academic insight with the drug discovery prowess of industry exemplifies a new paradigm in oncology research.

Opening the symposium, Damon Runyon President and CEO Yung S. Lie, PhD, alongside Damon Runyon Board member and BioNTech’s President of Research and Development Richard B. Gaynor, MD, and Amgen’s Executive Vice President of Research and Development James Bradner, MD, set an ambitious tone. Dr. Bradner, himself an alumnus of the Damon Runyon-Rachleff Innovator program, famously dubbed Damon Runyon a “triple-A team,” emphasizing how the foundation nurtures some of the most courageous and innovative scientific talents entering the biopharmaceutical sector.

The symposium featured several cutting-edge presentations from Damon Runyon-supported scientists, who are delving into the intricacies of cancer genomics and gene expression regulation. Mark Yarmarkovich, PhD, Lucas Farnung, PhD, Mary M. Mullen, MD, and Ziyang Zhang, PhD, each shared advances that aim to delineate the molecular signatures of various cancers to design highly precise, targeted therapies. Their work exemplifies the shift from broad-spectrum chemotherapeutics to tailored interventions that exploit tumor-specific vulnerabilities.

A keynote address delivered by Anna Farago, MD, PhD, Vice President of Early Development in Oncology at Amgen, and Julie Bailis, PhD, a former Damon Runyon Fellow and current Vice President of Oncology Research at Amgen, underscored the essential dialogue between preclinical data and clinical trial findings. Dr. Bailis articulated the tremendous value of iterative feedback loops between bench and bedside, a relationship imperative for refining therapeutic candidates and accelerating their journey through development pipelines.

Further illuminating the challenging landscape of difficult-to-treat malignancies, Damon Runyon investigators Megan A. Morrissey, PhD, Srivatsan Raghavan, MD, PhD, and Jonathan Chou, MD, PhD, discussed innovative approaches in combatting refractory cancers, including pancreatic adenocarcinoma. These types of malignancies, notorious for their resistance to conventional therapies and poor prognosis, demand novel therapeutic paradigms informed by deep mechanistic insights, such as targeting tumor microenvironmental factors or exploiting unique metabolic dependencies.

The afternoon session’s fireside chat, expertly moderated by Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences, brought together top translational oncology leaders—Jennifer Lauchte, MD (Novartis), Alex R. Shoemaker, PhD (AbbVie), and Louis Vermeulen, MD, PhD (Genentech). Their candid discussion highlighted the mechanics of successful collaboration in the drug development arena. Dr. Lauchte stressed the necessity of integrating multidisciplinary teams encompassing clinical trialists, molecular biologists, and medicinal chemists to generate comprehensive insights, avoiding siloed approaches that impede progress.

This symposium exemplifies the tangible benefits when academia and industry synchronize efforts to tackle cancer’s complexity. Dr. Lie and Margaret Faul, PhD, Vice President of Drug Substance Technologies and Site Head of Amgen Massachusetts, concluded the day by emphasizing the value of cross-disciplinary collaboration, noting that the Accelerating Cancer Cures initiative models how such partnerships can spur innovative therapeutic breakthroughs.

The ACC program’s strategy is rooted in empowering early-career clinical investigators by providing them with the funding and collaborative networks necessary to pursue high-risk, high-reward translational research. The iterative, bidirectional communication fostered between scientists, clinicians, and industry experts accelerates the identification of actionable biomarkers, validation of therapeutic targets, and the optimization of drug candidates. The promise of this synergy lies in shortening the timeline from scientific discovery to effective patient treatment.

Underlying the discussions at the symposium is an appreciation for the genomic and proteomic heterogeneity that defines malignancies. The presentations underscored the importance of leveraging next-generation sequencing technologies, CRISPR-based functional genomics, and sophisticated computational biology tools to unravel cancer’s molecular complexity. Such approaches enable the development of precision oncology strategies that account for tumor evolution, microenvironmental influences, and immune evasion mechanisms.

Moreover, the symposium shed light on the growing trend of integrating novel modalities, including bispecific antibodies, cell therapies, and targeted protein degraders in cancer therapeutics. These modalities, often emerging from deep academic research programs, require robust translational frameworks to ensure their effective clinical application. The ACC consortium’s commitment to facilitating these translational bridges is vital for capitalizing on these groundbreaking modalities.

In summary, the 2026 Accelerating Cancer Cures Research Symposium not only highlighted the impressive scientific advances driven by Damon Runyon scientists but also exemplified the power of collaborative ecosystems that unite academic ingenuity with industrial development capacity. With relentless dedication and strategic partnerships, the ambitions to transform cancer from a fatal diagnosis into a manageable condition have never been closer to fruition. This event stands as a beacon of hope and an illustration of how concerted collective efforts can accelerate the delivery of transformative cancer therapies to patients worldwide.

Subject of Research: Translational cancer research focused on accelerating discovery and development of targeted therapies through collaboration between academia and industry.

Article Title: Accelerating Cancer Cures: The 2026 Damon Runyon Symposium Sparks Dynamic Innovation in Oncology Therapeutics

News Publication Date: March 24, 2026

Web References:
– https://www.damonrunyon.org/
– https://www.amgen.com/
– https://www.novartis.com/
– https://www.genentech.com/
– https://www.abbvie.com/

Keywords: cancer genomics, targeted therapies, translational research, clinical innovation, collaboration, Damon Runyon, Accelerating Cancer Cures, oncology, pharmaceutical industry, molecular oncology, precision medicine, drug development

SPARK Scholars are embedded in research laboratories at leading institutions nationwide, collaborating closely with highly accomplished cancer researchers who have received Damon Runyon support in various capacities. Each scholar is awarded a stipend of up to $50,000, which includes a living allowance and travel funds to facilitate their engagement with the broader cancer research community. Over the course of the year, scholars participate in specialized programming aimed at fostering a sense of cohort identity and equipping them with essential skills to navigate the complex trajectory of a scientific career.

The program’s emphasis on mentorship is underscored by testimonials from inaugural scholars like Katelyn King, a current PhD candidate affiliated with St. Jude Children’s Research Hospital, who highlights the transformative power of guidance during formative stages of research training. King expresses her aspiration to emulate the mentorship she received when she establishes her own laboratory, emphasizing the critical role that early encouragement and professional network building play in shaping successful scientists.

Among the 2025 cohort, Isabella Alves distinguishes herself with a background rooted in biological sciences and chemistry at Pacific Lutheran University. Alves’s research focuses on the molecular interplay of isoprenoid biosynthesis and its dissociation impacts on hematopoietic stem cell (HSC) maintenance, proliferation, and survival—a vital area given the fundamental role of HSCs in blood formation and their vulnerabilities during oncological disruption. Her investigations in Professor Christina Termini’s laboratory at Fred Hutchinson Cancer Center are elucidating potential molecular targets for therapeutic interventions aimed at enhancing hematopoietic resilience.

Another notable scholar, Subyeta Chowdhury, representing the intersection of biological sciences with public health, has engaged deeply in projects investigating acute myeloid leukemia (AML) within the rigorous environment of Memorial Sloan Kettering Cancer Center. Under the mentorship of Dr. Ross Levine, a prominent figure in clinical cancer research, Chowdhury has contributed to dissecting the oncogenic mechanisms driving leukemogenesis. Her additional summer tenure as a Harvard-Amgen Scholar at Boston Children’s Hospital enabled her to examine clonal hematopoiesis, a process intimately connected with the emergence of AML through somatic mutations in hematopoietic progenitors.

Milen Negasi’s trajectory exemplifies convergence between neuroscience and oncology. Initially probing the regulatory dynamics of proteins such as midnolin in neuronal contexts at Harvard Medical School, her research expanded into broader cellular biological questions involving growth, differentiation, and apoptosis at Dana-Farber Cancer Institute. Working alongside Dr. Xin Gu, Negasi applies sophisticated molecular biology techniques to explore cellular signaling pathways that may underlie both neural plasticity and tumorigenesis, thus highlighting the interdisciplinary nature of contemporary cancer biology.

Imani Williams, a first-generation college graduate from Howard University, has channelled her passion into studying triple-negative breast cancer (TNBC), an aggressive and heterogeneous subtype lacking targeted therapies. Mentored by Dr. Jill Bargonetti at Hunter College, Williams’s work melds molecular genetics with translational oncology to uncover vulnerabilities within TNBC cells. Her commitment to advocacy and empowerment of marginalized communities resonates within the inclusive ethos of the SPARK program and represents the growing emphasis on diversity within the scientific workforce.

The SPARK program, by directly addressing the challenges faced by early career investigators—especially those from underrepresented backgrounds—aims to enhance both the quality and diversity of the future lines of cancer researchers. The combination of financial support, mentorship, and peer interaction is designed to reduce attrition rates commonly observed at this critical juncture and to bolster innovation that arises from diverse perspectives.

In a broader context, the Damon Runyon Cancer Research Foundation’s sustained investment of over $491 million since 1946 has supported nearly 4,100 scientists, fostering a research environment conducive to groundbreaking discoveries. This enduring commitment has been vindicated by the fact that thirteen Damon Runyon-supported scientists have been awarded the Nobel Prize, underscoring the foundational impact of early-stage funding and mentorship on the trajectory of cancer research.

The scientific questions pursued by the 2025 SPARK Scholars exemplify the multifaceted nature of cancer biology today, spanning molecular oncology, hematopoiesis, neuro-oncology, and cancer metabolism. By underpinning these investigations with mentorship from established Damon Runyon Fellows and Clinical Investigators, the program integrates rigorous experimental design, critical thinking, and clinically relevant inquiry.

As cancer research continues to evolve, programs like SPARK serve not only to train the next generation of scientists but also to catalyze the translation of fundamental discoveries into therapeutic strategies. The integrative structure of the program, which includes data presentation at the annual Damon Runyon Fellows’ Retreat, enriches the scholars’ experience by immersing them in a vibrant network of thought leaders and innovators, fostering collaborations that may ultimately expedite developments in cancer treatment.

The commitment to fostering an inclusive and supportive research culture is evidenced by the diverse personal backgrounds and research focuses of the SPARK Scholars, reflecting a microcosm of contemporary scientific enterprise. The connection between personal narratives and scientific motivation, as seen in the scholars’ profiles, underscores the human element driving cancer research forward.

Altogether, the Damon Runyon Scholars Program for Advancing Research and Knowledge represents a pivotal initiative dedicated to empowering young scientists to address one of the most pressing health challenges of our time. By investing in talent early and nurturing intellectual curiosity with robust scientific training and mentorship, the Foundation is helping to shape a future in which cancer’s complexities continue to be unraveled, and innovative treatments realized.

Subject of Research: Cancer biology, hematopoietic stem cell biology, molecular oncology, neuro-oncology, cancer metabolism, acute myeloid leukemia, triple-negative breast cancer.

Article Title: Damon Runyon Scholars Program Ignites Next Generation of Cancer Researchers with Mentorship and Cutting-Edge Investigations

News Publication Date: 2025

Web References: http://damonrunyon.org/

Keywords: Science education, Students, Minority students, Undergraduate education, Career advice, Scientific workforce, Minorities in science, Women in science, Young scientists

Over the past five years, the Quantitative Biology Fellows program has affirmed the critical importance of integrating robust computational skills with biological insight. These investigators are navigating the difficult terrain of cancer biology by deploying innovative theoretical frameworks alongside empirical evidence to decode intricate cellular mechanisms. They benefit from a unique funding structure, which provides $240,000 over three years and pairs postdoctoral scientists with dual mentors—an established computational scientist and a cancer biologist. This model fosters cross-disciplinary mentorship that is vital for the synthesis of quantitative and experimental approaches, enabling groundbreaking discoveries at the intersection of “wet” lab and “dry” lab research spheres.

One fellow, Dr. Simone Bruno at the Dana-Farber Cancer Institute, is focusing her work on triple-negative breast cancer (TNBC), one of the most aggressive and therapeutically challenging subtypes of breast cancer. Dr. Bruno’s research centers on the dynamics of chromatin—the structural arrangement of DNA and its regulatory proteins—and how directed alterations in this architecture influence cancer growth and resistance to therapies. Utilizing Bayesian inference to parameterize mathematical models that describe chromatin modification circuits, she intends to integrate these insights with pharmacokinetic and pharmacodynamic drug models. This composite computational framework aims to dissect the multifaceted mechanisms driving TNBC progression and resistance, potentially revealing novel intervention points to improve patient outcomes. Importantly, although TNBC serves as the model system, the methodologies developed here have broader applicability to diverse cancer types where chromatin remodeling is a pivotal factor.

At Memorial Sloan Kettering Cancer Center, Dr. Paul C. Klauser is pioneering computational protein design to overcome longstanding challenges in radiopharmaceutical development. Radiopharmaceuticals, which combine radioactive elements with targeting molecules, have transformed oncologic diagnostics and therapy but remain limited by the inefficiency of traditional chelators that bind radiometals. Dr. Klauser employs state-of-the-art diffusion models such as RFdiffusion to generate thousands of candidate protein scaffolds optimized for metal binding. These backbones are further refined using tools like ProteinMPNN and AlphaFold 3 to ensure structural stability and affinity for metals like copper, manganese, and lutetium. By engineering protein-based chelators capable of fusing with therapeutic antibodies, his computational methodology could vastly enhance the precision and efficacy of radiometal-based imaging and treatments, with a focus on HER2-positive gastric cancer yet far-reaching implications across cancers amenable to radiopharmaceutical interventions.

The adaptive immune response within tumor microenvironments is another frontier explored by Dr. Sohyeon Park at UCLA. Macrophages, specialized immune cells, exhibit “immune memory,” modifying their behavior based on previous antigen encounters, which can either inhibit or promote tumor progression. Despite recognition of this plasticity, the epigenetic and structural genomic basis of macrophage memory remains elusive. Dr. Park combines bulk Hi-C genomic data with machine learning-driven 3D chromosome reconstruction and deep learning image analysis to model how chromatin topology governs gene expression in macrophages. By quantifying spatial relationships between nuclear speckles and mRNA distribution, she seeks to mathematically characterize transcriptional regulation influenced by prior stimulation. This integrative computational and experimental approach aspires to unlock strategies for reprogramming macrophage memory, potentially tipping the balance toward enhanced anti-tumor immunity.

At the University of Texas Southwestern Medical Center, Dr. Ruoyu Wang addresses the enigmatic genomic “dark matter” of non-coding regions, which harbor regulatory elements vital to gene expression control and are frequently mutated in cancer. His innovative application of deep generative AI models to single-molecule regulatory genomics enables probabilistic exploration of chromatin state landscapes at DNA sequence resolution. By training these models on high-throughput genomic datasets, Dr. Wang’s framework can generate diverse hypothetical configurations of chromatin that reflect functional variability. This capability paves the way for high-fidelity annotation of the cancer regulatory genome, offering unprecedented granularity for discerning mutations that drive oncogenesis and identifying potential therapeutic targets within non-coding DNA.

The sophisticated temporal and spatial dynamics of gene regulation in cancer cells are the focus of Dr. Aaron Zweig’s work at the New York Genome Center. Employing stochastic differential equations to model gene expression trajectories over time, his computational pipeline incorporates provably identifiable linear and shallow neural networks optimized via adjoint differentiation techniques. Concurrently, spatial interactions among clustered transcriptomic data are analyzed through graph neural networks and self-attention mechanisms applied to latent gene embeddings derived from variational autoencoders integrating multi-modal RNA sequencing data. This approach uniquely captures both temporal variations and spatial heterogeneity in gene regulation, with particular relevance to acute myeloid leukemia (AML), where understanding transcriptional evolution could illuminate “precursor” cellular states and inform transplant immunotherapy strategies to minimize host tissue damage.

The Damon Runyon Cancer Research Foundation’s commitment to fostering such innovative quantitative research stems from its recognition that complex cancers demand equally complex and nuanced investigative tools. By supporting interdisciplinary collaborations that merge experimental oncology with computational modeling, Damon Runyon emphasizes the indispensable role quantitative biology plays in the era of personalized medicine. Through its intense selectivity—funding fewer than 10% of applicants—the Foundation ensures that only the most promising, visionary scientists gain support, promoting a culture of excellence that has historically propelled myriad breakthroughs, including multiple Nobel laureates.

The stories of these five fellows highlight how increasingly sophisticated computational methodologies are reshaping cancer research paradigms. From mathematical models simulating chromatin dynamics, deep learning–based structural genomics, protein engineering for radiotherapy, to complex neural network architectures capturing temporal-spatial gene regulation, these approaches exemplify the essential integration of quantitative rigor and biological insight. Their work stands as a testament to the transformative potential inherent in bridging computation and cancer biology—a synergy poised to deliver new therapeutic breakthroughs and precision interventions that could dramatically improve patient survival and quality of life.

As computational power and machine learning algorithms continue to evolve, the scientific community anticipates that such integrative frameworks will become standard tools within oncologic research. These fellows not only push the boundaries of knowledge but also exemplify the future of cancer research, where data-driven models and experimental validation go hand-in-hand to conquer one of medicine’s most formidable challenges. Their innovative projects reaffirm the belief that understanding cancer’s complexity at the molecular and cellular levels necessitates the convergence of diverse expertise, setting a new standard for collaborative science.

Subject of Research:

Cancer biology, computational biology, quantitative biology, chromatin dynamics, radiopharmaceutical design, immune cell epigenetics, regulatory genomics, machine learning, mathematical modeling.

Article Title:

Damon Runyon Names New Quantitative Biology Fellows Driving Computational Innovation in Cancer Research

News Publication Date:

Information not provided.

Web References:

http://damonrunyon.org

Keywords:

Cancer, Breast cancer, Quantitative analysis, Data analysis, Computational biology, Mathematical biology, Gene regulation, Mutation, Macrophages, Bioinformatics, Numerical analysis, Comparative analysis

Among this newest cohort of Damon Runyon Fellows, five have been distinguished with the Damon Runyon-Dale F. Frey Award for Breakthrough Scientists. This award serves to recognize those individuals who have shown exceptional promise and have already exceeded the Foundation’s high expectations to a degree that positions them for profound impacts on cancer research. To facilitate their ascent in the field and magnify their potential breakthroughs, the Foundation extends an additional investment of $100,000 to these outstanding recipients, further amplifying their opportunity to revolutionize cancer treatment and prevention.

One notable Fellow, Fangyu Liu, PhD, underscores the ambitious nature of the Fellowship, expressing how its emphasis on innovation has propelled her to investigate high-risk but potentially transformative ideas. She reflects on how this support has not only exceeded her expectations but has also equipped her to glean invaluable insights that could ultimately lead to landmark discoveries. This sentiment reflects a broader ethos of the fellowship: to prioritize bold scientific inquiry as a means of propelling the field of cancer research forward.

The work of the Fellowship recipients reflects diverse and innovative studies that span a wide array of cancer types and methodologies. Rongxin Fang, PhD, at Stanford University, is employing genomic tools to decipher the intricate interactions between enhancers and promoters in cancer at the single-cell level. He is particularly focused on understanding cell communication in the healthy brain and how such communication becomes disrupted in brain tumors. This work may uncover valuable insights into manipulating genetic pathways to improve therapeutic responses for patients suffering from brain cancer.

In a separate but equally critical area of research, Xin Gu, PhD, from Dana-Farber Cancer Institute, explores the midnolin-proteasome pathway and how it facilitates the degradation of proteins, bypassing traditional tagging mechanisms involving ubiquitination. This groundbreaking discovery holds significant implications for targeting key proteins linked to blood cancers like multiple myeloma. Dr. Gu aspires to unravel the finer details of this unique pathway to pave the way for novel therapeutic strategies that could dramatically alter treatment landscapes in hematological malignancies.

Fangyu Liu’s research occupies another vital niche in the fight against cancer, as she seeks to identify novel ligands to combat various cancers, including pancreatic and colorectal cancer. Through her innovative computational techniques, she screens vast libraries of chemical compounds, aiming to create highly specific drugs that effectively target cancerous pathways while sparing healthy tissues. Liu’s pioneering findings on calcium-sensing receptors underscore her commitment to shaping the future of cancer therapy, balancing efficacy with minimized side effects to potentially reshape standard care protocols.

Equally inventive, Akanksha Thawani, PhD, is confronting the fundamental question of how retrotransposons, often termed “selfish DNA,” propagate within the human genome. She applies cutting-edge cryo-electron microscopy to visualize the structural intricacies tied to these mobile genetic components. Thawani envisions her research leading to advances in genome editing technologies capable of addressing a myriad of genetic diseases, including various cancers, ultimately contributing to improved gene therapies.

Furthermore, Qinheng Zheng, PhD, is delving into the complexities of targeted therapy, specifically focusing on reactivating tumor suppressor genes like TP53, which are commonly mutated in numerous cancers. This research could signal a breakthrough in cancer therapeutics by offering new ways to counteract oncogenic mutations that currently hinder treatment options.

As the Foundation also welcomed a new class of Damon Runyon Fellows in November 2024, the research diversity continued to expand. For instance, Saket Rahul Bagde, PhD, investigates the dynamics of hemidesmosomes within cancerous epithelial tissues to facilitate the development of personalized therapies. Using organoids to simulate tumor environments, Bagde’s work could become instrumental in tailoring treatments based on individual patient profiles.

Likewise, Longyue Lily Cao, MD, PhD, focuses on enlightening the role of dendritic cells in hepatocellular carcinoma (HCC) to enhance anti-tumor immunity through immunotherapeutic approaches. Her studies aim to uncover methods to leverage hyperactivated dendritic responses, thus potentially reshaping strategies for cancers resistant to traditional immunotherapy.

Teng Gao, PhD, seeks to deep-dive into hematopoietic stem cells (HSCs), elucidating the molecular signals that govern HSC regeneration. By navigating the uncharted territories of age-related declines and regenerative capabilities of HSCs, his research aspires to enhance stem cell therapies, opening avenues for cancer treatment breakthroughs.

Rodrigo Gier, PhD, is employing a fundamentally varied strategy focused on addressing drug resistance in tumor cells. By creatively repurposing existing therapies through drug payload strategies, Gier aims to develop innovative methods that could selectively eliminate drug-resistant cancer populations, thus greatly improving clinical outcomes.

Through their collective efforts, this cohort of scientists exemplifies the cutting-edge frontline of cancer research. Their multi-faceted approaches—from cellular communication studies to novel therapeutic methods—demonstrate the expansive potential of innovative research to unveil new horizons in cancer treatment and prevention.

The contributions of the Damon Runyon Cancer Research Foundation, alongside the unwavering dedication of these exceptional researchers, symbolize a shared commitment to fighting cancer. With each breakthrough and each novel insight, they are transforming our understanding of cancer and paving the way for future advancements that promise to change the lives of countless patients.

Together, this dynamic landscape of research underscores a hopeful trajectory toward eradicating cancer and ensuring that new and effective therapies are continuously developed. As these Fellows embark on their respective paths, the cancer research community watches closely, eagerly anticipating the innovations that will surely emerge from their groundbreaking endeavors.

—

Subject of Research: Advanced Cancer Research Techniques and Innovations
Article Title: Pioneering Research in Cancer: Damon Runyon Fellows Push the Boundaries of Science
News Publication Date: October 2023
Web References: http://damonrunyon.org
References: Not Applicable
Image Credits: Not Applicable

Keywords
Damon Runyon Cancer Research Foundation, cancer research, postdoctoral scientists, therapeutic innovations, stem cell therapy, cancer immunotherapy, gene therapy, tumor suppressor genes, drug resistance, molecular signaling, personalized medicine, breakthrough scientists

Since its inception in 2024, the Damon Runyon-St. Jude Pediatric Cancer Research Fellowship has emerged as a crucial lifeline for ambitious scientists pursuing novel solutions to the complications inherent in treating children’s cancer. The initiative was established specifically to fill a glaring funding gap, which often compels elite researchers to divert their talents toward more prevalent adult cancer studies or lucrative roles in the pharmaceutical industry. This fellowship aims to redirect focus and resources back to the pressing needs in pediatric cancer research, fostering an environment where collaboration and innovation can flourish.

Under the leadership of prestigious field experts, a selection committee comprised of luminaries in pediatric oncology carefully scrutinizes candidates. These rigorous evaluations ensure that only the most talented and visionary researchers will receive this fellowship. Dr. James R. Downing, CEO and president of St. Jude, highlighted the partnership’s purpose, emphasizing its role in propelling researchers toward groundbreaking developments that could change the paradigm of childhood cancer therapy and management. The advancements achieved through this fellowship will contribute significantly to fulfilling St. Jude’s mission of curing and saving children across the globe.

One of the notable areas of research being tackled by the fellows revolves around diffuse midline gliomas (DMG). These pediatric brain tumors represent a critical challenge in oncology, known for their uniform lethality and resistance to current treatments. Dr. Ian Blumenthal, teaming up with Jim M. Olson, aims to pioneer new immune cell engagers capable of prompting a patient’s immune system to combat these tumors. His project focuses on leveraging the inherent variability of DMGs while preserving healthy tissue, which could result in treatments that not only enhance efficacy against pediatric gliomas but also advance the field of immunotherapy overall.

Fellow Matthew Decker is tackling acute myeloid leukemia (AML), a notoriously challenging form of cancer to cure among children. Current therapies are often fraught with harsh side effects that leave survivors vulnerable to long-term health complications. Dr. Decker’s innovative approach involves disrupting the N-Ras protein, a common mutation in pediatric AML, which could potentially sensitize cancer cells to existing treatments. His findings could usher in a new wave of therapies that prioritize patient well-being and minimize the toxic impact of conventional treatments.

Dr. Oriana Miltiadous is delving into the intricate relationship between the gut microbiome and immune responses in children undergoing allogeneic hematopoietic cell transplantation (allo-HCT). While allo-HCT can be life-saving for aggressive cancers like leukemia, it often triggers dangerous complications. By investigating the role of bile acids produced by gut microbiota, she hopes to identify methods for balancing immune responses, preventing inflammation, and ultimately enhancing recovery rates in young patients. Her work promises to yield transformative insights into the developing field of microbial influences on cancer therapy.

In a further inquiry into immune mechanisms, Dr. Geoffrey Smith is set to explore why immunotherapies have been largely ineffective in treating pediatric solid tumors such as osteosarcoma—the most common bone cancer in children. Utilizing a novel mouse model that replicates human osteosarcoma while retaining an intact immune system, Dr. Smith’s research aims to unveil barriers that hinder immune system activation against these tumors. His insights could lead to the design of more targeted immunotherapies that have the potential to dramatically alter patient outcomes in this challenging area of pediatric oncology.

Dr. Lara Wahlster’s research targets the developmental origins of acute lymphoblastic leukemia (ALL), the leading cause of cancer-related deaths in children. By applying advanced genomic techniques, she aims to uncover the biological processes that predispose children to blood cancers, providing a foundation for understanding the mechanisms at play. Her work is anticipated to yield novel therapeutic strategies that are informed by the genetic underpinnings of ALL, ultimately fostering advancements in treatment paradigms.

Fellow Tuyu Zheng is addressing ependymoma, a particularly aggressive brain tumor that proves challenging to manage in pediatric populations. Researching the interactions between tumor cells and healthy neurons, Dr. Zheng aims to map out how neuronal environments contribute to the growth of ependymomas. Her findings could pave the way for groundbreaking interventions and treatment strategies tailored to combat these resilient tumors, transforming care methodologies and improving prognoses.

Each of these pioneering research projects signifies a commitment to propelling pediatric cancer research into uncharted territories. By equipping the next generation of scientists with the necessary resources and support, the Damon Runyon-St. Jude fellowship is laying the groundwork for future advances. As these young researchers embark on their journeys to unravel the complexities of childhood cancers, their work holds the promise of substantially improving treatment options and transforming patient care.

The establishment of this fellowship illustrates a broader movement within the scientific community aimed at elevating the profile of pediatric cancer research. As adults have long dominated the funding landscape due to the prevalence of their diseases, the spotlight now turns to the urgent needs of children battling cancer. The acknowledgment of this gap and the proactive measures taken to address it through the Damon Runyon-St. Jude fellowship reflect a growing recognition of the unique challenges faced by pediatric patients.

Such initiatives not only optimize funding opportunities but also inspire a collaborative spirit among scientists, medical professionals, and institutions dedicated to fighting childhood cancer. The fellowship embodies the idea that holding our commitments to the youngest members of society can yield impactful results and foster an environment ripe for scientific inquiry. With commitment and collaboration, the future of pediatric cancer research appears promising, as these fellows step forward to illuminate new pathways in the pursuit of cures.

Through this fellowship’s collaborative initiatives, significant strides can be made in pediatric cancer treatment options, showcasing the importance of investment in specialized research. The efforts of fellows like Dr. Blumenthal, Dr. Decker, Dr. Miltiadous, Dr. Smith, Dr. Wahlster, and Dr. Zheng exemplify the dedication to addressing the nuances of pediatric cancer, ensuring that future generations may not only survive these diseases but also thrive beyond them.

As media outlets spread awareness of this groundbreaking fellowship, the hope is that more institutions will recognize the critical importance of pediatric cancer research. By fostering talent and providing financial support for innovative projects, we can pave the way for a transformative revolution in the quality and efficacy of treatments available for young patients.

Subject of Research: Pediatric Cancer Research Fellowship
Article Title: Transformative Research Initiatives in Pediatric Oncology
News Publication Date: February 13, 2025
Web References: Damon Runyon Cancer Research Foundation, St. Jude Children’s Research Hospital
References: None
Image Credits: Damon Runyon Cancer Research Foundation and St. Jude Children’s Research Hospital

Keywords: Pediatric cancer research, immunotherapy, leukemia, research fellowship, childhood cancer, ependymoma, gut microbiome, innovative treatments.

Among the five new recipients of the award, Dr. Yiyin Erin Chen from the Broad Institute of MIT and Harvard is poised to explore an intriguing angle in cancer immunotherapy. Dr. Chen’s research proposal centers around skin commensal bacteria, the harmless microorganisms that inhabit our skin. Her objective is to uncover mechanisms whereby these bacteria can stimulate a systemic antitumor response. By identifying which skin cells can relay these bacterial signals to immune cells, she aims to create a novel cancer vaccine strategy that uses engineered versions of these bacteria. This innovative approach targets melanoma initially but holds promise for broader applications across various cancer types.

Dr. Meghan A. Morrissey, representing the University of California, Santa Barbara, introduces an equally compelling project focused on macrophages—the immune cells responsible for engulfing pathogens and cancer cells. Her research aims to enhance the effectiveness of immunotherapies that harness macrophages for tumor cell destruction, specifically in cases of Her2-positive breast and ovarian cancers. By investigating the phenomenon known as trogocytosis, where macrophages nibble cancer cells rather than completely engulfing and destroying them, Dr. Morrissey hopes to convert this seemingly ineffective process into a potent mechanism for cancer cell death.

At Rutgers, Dr. Natasha O’Brown is tackling a formidable obstacle in glioblastoma treatment—the blood-brain barrier (BBB). This protective barrier often limits the efficacy of chemotherapeutic agents. Dr. O’Brown proposes to utilize zebrafish models to identify small molecules capable of temporarily increasing BBB permeability, thereby improving drug delivery to brain tumors. Her research not only seeks to identify these molecules but also aims to engineer specialized zebrafish models to validate her findings in mammalian systems. This innovative concept proposes a promising avenue toward enhanced treatment regimens for patients grappling with aggressive brain cancers.

Memorial Sloan Kettering Cancer Center’s Dr. Justin Perry is redirecting attention to the interplay between tumor cells and immune cells within the tumor microenvironment. Focusing on triple-negative breast cancer, a particularly aggressive form of the disease, Dr. Perry’s investigations delve into how macrophages contribute to the metabolic needs of tumor cells. By manipulating and imaging cellular metabolism, his work promises to unveil crucial insights about the nutrient-sharing dynamics that allow cancer cells to thrive. This research could pave the way for personalized treatment strategies, significantly impacting patient outcomes and redefining therapeutic approaches for various metastatic cancers.

Another innovative mind, Dr. Mark Yarmarkovich from New York University Grossman School of Medicine, is pushing the boundaries of CAR T-cell therapy. While CAR T-cell therapy has successfully transformed cancer treatment for some patients, the majority of patients still lack access to effective treatments due to challenges in identifying suitable tumor-specific targets. Dr. Yarmarkovich’s proposal aims to broaden the scope of CAR therapy by utilizing a new class of CAR T cells that target intracellular proteins—the key drivers of tumors traditionally beyond the reach of current CAR technology. This paradigm-shifting approach could not only enhance the efficiency of existing therapies but also expand the patient population that can benefit from these cutting-edge treatments.

In addition to the five new Innovators, the Damon Runyon Foundation also recognized three current Innovators who have demonstrated significant progress and have been granted Stage 2 continuation support. Dr. Lucas Farnung from Harvard Medical School aims to decode the complexities of gene expression regulation in cancers stemming from MLL translocations, which represent a significant portion of pediatric and adult leukemias. His use of biophysical methods to visualize the molecular mechanics at play promises a deeper understanding of these cancers and could lead to new therapeutic avenues.

Similarly, Dr. Ryan A. Flynn from Boston Children’s Hospital is delving into the world of cell surface ligands in acute myeloid leukemia (AML). His research intends to identify RNA structures on the surface of AML cells and develop antibodies capable of selectively targeting and eliminating these cancer cells. The implications of this groundwork may extend beyond AML, opening new doors for diagnostics and therapeutics in various cancer types.

Finally, Dr. (Kathy) Fange Liu from the University of Pennsylvania will examine the Y chromosome-encoded proteins that exhibit significant involvement in cancer development across non-reproductive tissues. By understanding how these proteins differ from their X chromosome counterparts, Dr. Liu aims to elucidate their role in sex-biased cancer disparities. This exploration into sex differences in cancer could lead to more tailored approaches in treatment and highlight the necessity of considering biological sex in cancer research.

The Damon Runyon Cancer Research Foundation’s commitment to innovative research reflects a broader understanding that pivotal breakthroughs often arise from bold, unconventional ideas. By nurturing early-career researchers through the Innovation Award, the Foundation plays a vital role in empowering scientists to explore untapped avenues in cancer research. Each of the awardees exemplifies not only an innovative spirit but also a dedicated commitment to improving the lives of cancer patients by addressing critical gaps in current knowledge and treatment modalities.

As we examine the ambitious pursuits of these trailblazers, it becomes evident that the future of cancer research lies in the convergence of diverse scientific disciplines and innovative methodologies. The combination of their unique perspectives and cutting-edge research approaches represents a collaborative effort to tackle one of humanity’s most persistent challenges. In a world where the fight against cancer remains a pressing concern, the determination and creativity showcased by these researchers provide hope for transformative advancements in diagnosis, treatment, and ultimately, prevention.

Subject of Research: Innovative Cancer Therapies
Article Title: Trailblazing Research in Cancer: 2025 Damon Runyon-Rachleff Innovation Award Recipients Announced
News Publication Date: [Insert Publication Date]
Web References: [Add Relevant Links]
References: [Add Relevant Literature]
Image Credits: [Add Image Credit Information]

Keywords: Cancer research, immunotherapy, melanoma, glioblastoma, CAR T cells, leukemia, metabolic symbiosis, blood-brain barrier, trogocytosis, Y chromosome, antibody development.